-
Deuterated Azole CYP51 Inhibitors: Advances in Antifungal De
2026-06-13
This study introduces a novel class of deuterated diphenyl azole alcohol-based CYP51 inhibitors, leveraging molecular hybridization strategies to improve antifungal potency, selectivity, and pharmacokinetics. The findings highlight compound C52’s broad-spectrum efficacy—including against drug-resistant Candida—and establish a chemical basis for next-generation antifungal development.
-
Puerarin Regulates Gut Microbiota and Adipose Thermogenesis
2026-06-12
This study demonstrates that puerarin, a natural compound from Pueraria lobata, improves glucose and lipid metabolism in type 2 diabetic mice by restoring gut microbiota balance and enhancing adipose tissue thermogenesis. The findings deepen mechanistic understanding of phytotherapeutic strategies for T2D and highlight the importance of preserving protein integrity in signaling pathway research.
-
Recombinant Mouse Macrophage Colony Stimulating Factor: Appl
2026-06-12
Unlock the full potential of macrophage-based research with Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) without Tag, optimized for reproducible survival, proliferation, and functional polarization. This guide details proven protocols, experimental enhancements, and troubleshooting strategies, bridging recent macrophage metabolism discoveries with practical lab execution.
-
hiPSC-Derived Intestinal Organoids for CYP2C19 Substrate Stu
2026-06-11
This study developed a streamlined protocol for generating human induced pluripotent stem cell (hiPSC)-derived intestinal organoids suitable for pharmacokinetic analysis of drug metabolism. The organoids exhibit stable differentiation and relevant cytochrome P450 activity, providing a more physiologically representative in vitro model for evaluating substrates such as (S)-Mephenytoin.
-
DDI2-NFE2L1 Pathway Protects Cells from Ferroptosis via UPS
2026-06-11
This study uncovers a critical role for the DDI2-NFE2L1 axis in maintaining proteasome function and protecting cells from ferroptosis, an iron-dependent, non-apoptotic cell death mechanism. The findings suggest that targeting this pathway—using genetic or pharmacological inhibitors like Nelfinavir Mesylate—may sensitize cancer cells to ferroptosis, providing novel therapeutic opportunities.
-
Rhodamine B as a Quantitative Fluorescent Probe in Drift and
2026-06-10
Rhodamine B (Basic Violet 10) bridges precision environmental monitoring and advanced cell labeling, excelling as both a quantitative drift tracer and robust fluorescent probe for microscopy. This article details optimized protocols, experimental enhancements, and field-tested troubleshooting to maximize assay reproducibility across environmental and biomedical workflows.
-
Targeting Glutamine Metabolism in HSCs to Alleviate Liver Fi
2026-06-10
This study elucidates how inhibition of glutamine metabolism in hepatic stellate cells (HSCs) mitigates the progression of liver fibrosis. By detailing the role of SIRT4-mediated regulation of GDH and the effect of metabolic intervention, the work advances therapeutic strategies for chronic liver disease.
-
Cyclosporin A in Research: Protocols, Applications, and Opti
2026-06-09
Cyclosporin A remains the gold standard for dissecting T-cell signaling and mitochondrial regulation in both in vitro and in vivo models. This guide translates the latest peer-reviewed findings and proven laboratory workflows into actionable steps for reliable immunosuppression assays, highlighting APExBIO’s Cyclosporin (SKU B8309) as a trusted reagent for precision and reproducibility.
-
hiPSC-Derived Intestinal Organoids for CYP2C19 Substrate Stu
2026-06-09
This study establishes a streamlined protocol for generating human induced pluripotent stem cell (hiPSC)-derived intestinal organoids capable of long-term propagation and functional maturation. The approach enables robust in vitro pharmacokinetic investigations, including those involving CYP2C19 substrates such as (S)-Mephenytoin, with improved physiological relevance over traditional models.
-
Itraconazole (SKU B2104): Optimizing Antifungal Assays in th
2026-06-08
This article delivers scenario-driven guidance for harnessing Itraconazole (SKU B2104) in advanced cell viability and antifungal assays. By addressing common workflow and data interpretation challenges, it highlights how Itraconazole’s validated formulation supports reproducibility, sensitivity, and compatibility for modern Candida research and drug interaction studies.
-
HyperFluor 488 Goat Anti-Human IgG Antibody: Applied Workflo
2026-06-08
The HyperFluor 488 Goat Anti-Human IgG (H+L) Antibody delivers unmatched specificity and signal amplification in immunofluorescence, Western blotting, and flow cytometry. Its Alexa Fluor 488 conjugation ensures reproducible, quantitative results and empowers researchers to overcome common assay pitfalls, streamlining advanced immunodetection workflows.
-
Fluconazole in Antifungal Resistance: Mechanisms and Biofilm
2026-06-07
Explore how Fluconazole, a potent fungal cytochrome P450 enzyme 14α-demethylase inhibitor, illuminates the complex landscape of antifungal drug resistance and biofilm adaptation in Candida albicans. This article uniquely bridges mechanistic insights with practical assay guidance for advanced research.
-
2-(4,5,6,7-tetrabromo...)acetic acid: Small Molecule Inhibit
2026-06-06
Unlock precision in phase separation and kinase signaling studies with 2-(4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)acetic acid. This advanced small molecule inhibitor offers robust workflow flexibility for dissecting protein-protein interactions, phosphorylation events, and enzyme-mediated condensate formation. Discover optimized protocols, troubleshooting insights, and innovative research applications that set this CK2 and ERK8 inhibitor apart.
-
Açaí Extracts: Hepatocyte Cytotoxicity and Enzyme Modulation
2026-06-05
This study systematically investigates the cytotoxic and drug-metabolizing enzyme induction potential of various açaí (Euterpe oleracea) extracts in human hepatocytes. The findings highlight extract-dependent cytotoxicity without significant induction of CYP450 enzymes or transporters, informing risk assessment for botanical-drug interactions in pharmacological research.
-
Bedaquiline: Redefining Bioenergetic Targeting in TB and Onc
2026-06-05
Explore how Bedaquiline, a diarylquinoline antibiotic, uniquely disrupts bioenergetics in both multi-drug resistant tuberculosis and cancer stem cells. This deep-dive uncovers mechanistic nuances, translational assay considerations, and the evolving landscape of host-directed therapies.